Corcept Therapeutics (NasdaqCM:CORT) saw a remarkable 36% increase in its share price in the last quarter, driven by several key developments. The company's significant announcement on March 31, ...

The following seven stocks all are riding different good news updates to recent gains right now. That doesn't guarantee that ...

To optimize treatment outcomes for patients whose late-stage cancer shows resistance to the standard treatment, Sarasota Memorial Research Institute will participate in testing an experimental ...

Patients in the pembrolizumab-olaparib arm had clinically meaningful improvements in PFS over patients in the control arm.